NuwellisNUWE
NUWE
About: Nuwellis Inc is a medical device company. Its solutions includes Aquadex Smartflow System and RenalSense Clarity RMS. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Clarity RMS is a kidney monitoring system that continuously measures urine output and flows, automatically displaying real-time data to the medical staff.
Employees: 59
0
Funds holding %
of 7,363 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
117% more capital invested
Capital invested by funds: $42.2K [Q3] → $91.5K (+$49.4K) [Q4]
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
17% more funds holding
Funds holding: 6 [Q3] → 7 (+1) [Q4]
0.01% less ownership
Funds ownership: 1.89% [Q3] → 1.89% (-0.01%) [Q4]
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Research analyst outlook
We haven’t received any recent analyst ratings for NUWE.
Financial journalist opinion
Based on 7 articles about NUWE published over the past 30 days
Neutral
Seeking Alpha
12 hours ago
Nuwellis, Inc. (NUWE) Q4 2024 Earnings Call Transcript
Nuwellis, Inc. (NASDAQ:NUWE ) Q4 2024 Earnings Conference Call March 11, 2025 9:00 AM ET Company Participants Vivian Cervantes - Gilmartin Group, Investor Relations John Erb - Interim President and Chief Executive Officer Rob Scott - Chief Financial Officer Conference Call Participants Jonathan Aschoff - Roth Anthony Vendetti - Maxim Group Operator Good morning. And welcome to Nuwellis Earnings Conference Call for the Fourth Quarter and Full Year ended December 31, 2024.
Negative
Zacks Investment Research
13 hours ago
Nuwellis, Inc. (NUWE) Reports Q4 Loss, Lags Revenue Estimates (Revised)
Nuwellis, Inc. (NUWE) came out with a quarterly loss of $0.65 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $78.32 per share a year ago.
Negative
Zacks Investment Research
14 hours ago
Nuwellis, Inc. (NUWE) Reports Q4 Loss, Lags Revenue Estimates
Nuwellis, Inc. (NUWE) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $78.32 per share a year ago.
Neutral
GlobeNewsWire
16 hours ago
Nuwellis, Inc. Announces Fourth Quarter and Full Year 2024 Financial Results
MINNEAPOLIS, March 11, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage medical device company focused on transforming the lives of people with fluid overload, today reported financial results for the fourth quarter and full year ended December 31, 2024.
Neutral
GlobeNewsWire
2 weeks ago
Nuwellis Announces Retirement of Nestor Jaramillo, Jr. as President and CEO
John Erb, Current Chair of the Board, Appointed Interim President and CEO John Erb, Current Chair of the Board, Appointed Interim President and CEO
Neutral
GlobeNewsWire
2 weeks ago
JACC: Heart Failure Paper Reports Promising Findings of Aquadex Therapy in Updated AVOID-HF Study Analysis
MINNEAPOLIS, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage medical device company focused on transforming the lives of people with fluid overload, today highlighted promising findings from an updated analysis of the AVOID-HF study, recently published in the Journal of the American College of Cardiology: Heart Failure. The analysis, led by Dr. Sean P. Pinney, Chief of Cardiology at Mount Sinai Morningside and Chief of Nephrology at Lenox Hill Hospital, Dr. Maria V. DeVita, provides new insights suggesting the potential benefits of Aquadex® SmartFlow ultrafiltration therapy in managing heart failure. The analysis found that patients treated with Aquadex therapy demonstrated a 60% reduction in heart failure events at 30 days compared to those receiving traditional IV diuretics.
Neutral
GlobeNewsWire
3 weeks ago
Nuwellis, Inc. To Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025
MINNEAPOLIS, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the fourth quarter and full year 2024 on March 11, 2025. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update.
Neutral
GlobeNewsWire
2 months ago
Nuwellis Regains Compliance with Nasdaq Listing Requirements
MINNEAPOLIS, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (the “Company” or “Nuwellis”) today announced that the Company received formal written notice from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Nasdaq's minimum bid price requirement (the “Bid Price Requirement”) set forth in Nasdaq Listing Rule 5550(a)(2), as well as Nasdaq's stockholders' equity requirement (“Equity Requirement”) set forth in Nasdaq Listing Rule 5550(b)(1). The Company's Common Stock will continue to trade on The Nasdaq Capital Market tier of Nasdaq under the symbol "NUWE".
Neutral
Seeking Alpha
3 months ago
Nuwellis, Inc. (NUWE) Q3 2024 Earnings Call Transcript
Nuwellis, Inc. (NASDAQ:NUWE ) Q3 2024 Earnings Call Transcript November 11, 2024 9:00 AM ET Company Participants Vivian Cervantes - IR Nestor Jaramillo - President and CEO John Jefferies - CMO Rob Scott - CFO Conference Call Participants Jonathan Aschoff - Roth Anthony Vendetti - Maxim Group Operator Good day, everyone, and Welcome to Nuwellis' Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Positive
Zacks Investment Research
3 months ago
Nuwellis, Inc. (NUWE) Q3 Earnings Surpass Estimates
Nuwellis, Inc. (NUWE) came out with quarterly earnings of $1.74 per share, beating the Zacks Consensus Estimate of a loss of $0.88 per share. This compares to loss of $63.29 per share a year ago.
Charts implemented using Lightweight Charts™